Whittaker's $535 Million Talc Deal Was Approved Over Claimants' Objections — and Berkshire Walks Away Shielded

On October 22, 2026, a New Jersey bankruptcy judge approved a $535 million settlement resolving talc liabilities tied to defunct supplier Whittaker Clark & Daniels, overruling claimants who called the deal too small and asked to sue Berkshire Hathaway affiliates directly.

  • $535 million: the aggregate payment by the settling non-debtors — the Brenntag entities, National Indemnity Company (NICO), and DBUS — to the Whittaker bankruptcy estate.
  • About 2,700 people: the number whose lawsuits at filing alleged Whittaker supplied asbestos-contaminated talc that caused cancer.
  • $5.3 billion versus under $520 million: the competing expert valuations of the claims — claimants' experts at the top end, Berkshire's experts at the bottom.
  • October 22, 2026: Judge Michael B. Kaplan's memorandum opinion granting the settlement and denying claimants' bid to pursue the claims themselves.
  • 2007: the year National Indemnity, Berkshire Hathaway's insurance unit, purchased Whittaker and assumed its liabilities.

Background explainers on cases like this appear on the Problem Solved channel.

What Judge Kaplan Actually Decided

Judge Michael B. Kaplan of the United States Bankruptcy Court for the District of New Jersey ruled the Whittaker settlement fair and reasonable — a legal conclusion, not a compliment, weighing the claims' value, the claimants' chances against Whittaker's former parents, and the cost and delay of fighting on.

In the same opinion, Kaplan denied derivative standing — permission for someone other than the bankruptcy estate to pursue a claim belonging to the estate. The claimants' committee and the future claimants' representative had sought it to sue Brenntag, National Indemnity, and other successors directly for a larger contribution. Kaplan refused: Whittaker itself, through its estate, must pursue indemnification and contribution claims against those companies.

One detail matters: the October 22 document was a memorandum opinion directing Whittaker's lawyers to settle an appropriate order putting the ruling into effect. That order, not the opinion alone, is the document administrators and claims handlers will work from, so money should not be assumed to move immediately.

Who Whittaker Clark & Daniels Was — and Why This Is Not the Johnson & Johnson Case

Whittaker Clark & Daniels was a talc supplier, not a household brand. Lawsuits alleged it supplied asbestos-contaminated talc to makers of cosmetics, chemicals, and other products, and that people exposed through those products developed cancer. Whittaker filed for Chapter 11 bankruptcy protection in 2023 amid a deluge of lawsuits. Chapter 11 lets a company reorganise under court supervision of its debts and liabilities, rather than simply liquidating.

That supplier position is why this case must not be confused with the Johnson & Johnson talc litigation over its own consumer products. In July 2026, Johnson & Johnson proposed a $5.5 billion settlement for roughly 76,000 ovarian cancer claims, conditional on at least 95 percent participating, with firms holding about 87.5 percent signed on. Whittaker's fight was never about a consumer brand's labelling, but about whether companies that once owned or distributed a supplier's talc should pay more than the estate negotiated.

Readers tracking the larger talc bankruptcy landscape should also read how talc bankruptcy trusts, trial verdicts, and claim deadlines fit together, which explains why some talc claims end up paid through a trust while others proceed in court.

The Valuation Gap: $535 Million Against a $5.3 Billion Claim

The starkest numbers are the two valuations beside the settlement. Claimants' experts put the claims as high as $5.3 billion; Berkshire's experts put them below $520 million. The approved $535 million sits just above Berkshire's figure and roughly one-tenth of the claimants' top estimate — why claimants called the deal an insider arrangement shielding wealthy companies.

A bankruptcy judge need not split the difference between expert estimates. Kaplan's task was whether the settlement fell within a range of reasonableness given litigation risk: the chance that claims against former parents would fail on successor-liability law, and the years and expense of pursuing them. The Court of Appeals for the Third Circuit had already strengthened the estate's hand, holding that product-line successor-liability claims against Brenntag are property of the bankruptcy estate under section 541 of the bankruptcy code. A bankruptcy estate is the debtor's pool of assets and claims, administered for creditors; a claim in that pool cannot be seized by individuals suing on their own.

None of this means any individual claimant receives a particular sum. Compensation varies widely by case, and most settlements are confidential in their allocation details. The $535 million is an aggregate fund paid to the estate, not a per-person promise; how it is divided depends on the bankruptcy plan and the claims process.

Why Claimants Cannot Sue Berkshire Directly Now

The claimants' central complaint was about control as much as money: the settlement was negotiated between Whittaker and its corporate owners and affiliates without their input, resolving the liabilities of National Indemnity, Berkshire Hathaway, Brenntag, and others with a shared history. Kaplan denied direct suit for a structural reason: claims against those affiliates, resting on the debtor's own rights, belong to the estate, and letting individuals usurp them would fragment one pool into competing lawsuits.

That ruling does not end every avenue. Lawyers for asbestos claimants have said they intend to appeal, challenging both the fairness finding and the standing denial. Appeals in bankruptcy cases are slow, and appellate courts defer considerably to a bankruptcy judge's reasonableness assessment — but an appeal preserves the argument that $535 million undervalues the claims and that the negotiation lacked independence.

Claimants also challenged the independent directors, pointing to connections between Kirkland & Ellis, the debtor's bankruptcy counsel, and Berkshire-related parties. Kaplan found insufficient evidence of improper influence — a finding future mass-tort lawyers will cite alongside the estate-property ruling.

What Happens Next: Order, Appeal, and the Path to Payment

Four things decide what the ruling is worth: the formal order's wording on which liabilities and entities are covered; any appeal, which could delay distributions; and the Chapter 11 plan and claims process, which set who qualifies, what proof is required, and when payments begin. Fourth, the separate environmental settlement approved the same day: National Indemnity funds $16.5 million against $57 million in stipulated allowed claims, resolving legacy pollution across five California and Montana sites, including a Billings Superfund site. That money is distinct from the talc injury fund.

Anyone who believes they have a Whittaker-related claim should preserve records linking them to a Whittaker-supplied talc product, note diagnosis and exposure dates, and watch for the court's claims process rather than assuming the October ruling opens a payment window. Bankruptcy deadlines are set by court order and can be unforgiving.

Who Benefits From This — and Who Does Not

People with a diagnosed asbestos-related disease traceable to a Whittaker-supplied talc product benefit most directly: the settlement funds an estate that can pay their claims without years of litigation against a defunct company with no operating business. Families of deceased claimants benefit the same way, through estate and survivor claims.

People exposed only through Johnson & Johnson consumer talc products do not benefit at all; their claims belong to a different litigation, starting with the talc bankruptcy trust and deadlines guide. Similarly, people with mesothelioma from a different asbestos source — a shipyard, a factory, or another supplier — gain nothing from Whittaker's fund unless they can show a Whittaker link; for that different route, see how asbestos-contaminated talc claims differ from other mesothelioma cases.

Finally, people who hoped to sue Berkshire Hathaway directly do not get that outcome here: derivative standing was denied, and that path now depends on an appeal. And anyone without a diagnosis or documented exposure link gains no payment — this fund is for people harmed, not everyone who ever used a talc product.

Frequently Asked Questions

What did Judge Kaplan approve on October 22, 2026?

He approved a $535 million settlement in the Whittaker Clark & Daniels bankruptcy, under which the Brenntag entities, National Indemnity Company, and DBUS pay that aggregate sum to the bankruptcy estate in exchange for releases of specified liabilities, and he denied claimants' request to sue those companies directly.

Who benefits from the Whittaker settlement?

People with an asbestos-related disease who can trace exposure to products made with Whittaker-supplied talc, and the families of deceased claimants in the same position, benefit because the settlement funds the estate that pays their claims.

Who does not benefit, or cannot use this settlement?

People whose only talc exposure came from Johnson & Johnson consumer products, people whose mesothelioma came from a different asbestos source with no Whittaker link, and people without a diagnosis or documented exposure do not benefit from this fund.

How do I benefit, or how do I start a Whittaker claim?

Preserve records linking you to a product made with Whittaker-supplied talc, note your diagnosis and exposure dates, and watch for the claims process the bankruptcy court establishes under the Chapter 11 plan; then file in that process before its court-set deadline.

Why did claimants call $535 million too small?

Their experts valued the claims at as much as $5.3 billion, while Berkshire's experts valued them below $520 million, so claimants argued the deal shields wealthy affiliates for roughly one-tenth of their top estimate; the judge instead found the settlement reasonable given litigation risk.

Is the $535 million the same as the Johnson & Johnson talc settlement?

No. Johnson & Johnson's July 2026 proposal was $5.5 billion for roughly 76,000 ovarian cancer claims tied to its own consumer products, while Whittaker's $535 million concerns a defunct supplier's talc and about 2,700 claimants at filing.

This article is general information about a court ruling and a device recall, not legal or medical advice. If you believe you were harmed, speak promptly with a qualified lawyer or clinician about your own facts and deadlines.

Watch on YouTube

Problem Solved on YouTube